According to researchers in Italy, patient characteristics such as glycaemic control, body mass index, and lipid profile can significantly affect the risk of cardiovascular events in rosiglitazone-treated patients with type 2 diabetes.
11.11.2008
group of researchers led by Dr Edoardo Mannucci at the Azienda Ospedaliero - Universitaria Careggi in Florence, Italy, investigated the possible role of rosiglitazone in an increased risk of myocardial infarction (MI) and chronic heart failure (CHF) in patients with type 2 diabetes. A total of 86 trials were included in the investigation, which assessed the risk ratio for MI and CHF in rosiglitazone-treated patients using baseline HbA1c, triglyceride, and LDL cholesterol levels; body mass index (BMI); and prior treatment with insulin as disease indicators.
Read more
|
 |
Does self-monitoring of blood glucose improve glycaemic control?
11.11.2008
According to researchers in the USA, self-monitoring of blood glucose can improve glycaemic control in patients with type 2 diabetes currently being treated with oral hypoglycaemic agents.
Read more
|
Tip a Colleague
